Jasper 8-K/A details Kira merger financials: FY2025 net loss $4.4M, going-concern doubt, $132M preferred financing

Jasper Therapeutics, Inc.

Kira reported FY2025 net loss of $4.4M (vs $4.8M in FY2024); R&D expense fell to $0.9M from $2.8M and G&A was $1.5M.
Auditor EisnerAmper cited substantial doubt about Kira's ability to continue as a going concern; accumulated deficit was $180.8M with only $0.6M cash at Dec 31, 2025.
Concurrent private placement of non-voting convertible preferred stock raised $132.0M gross; Jasper must seek stockholder conversion vote within 120 days of the July 16, 2026 merger close.
If conversion isn't approved in 12 months, holders can require Jasper to repurchase the preferred at fair value; the deal also includes contingent value rights and a Mirador License Agreement.
Kira's Dec 31, 2025 balance sheet showed $1.1M total assets vs $8.9M liabilities, including $6.4M trade payables; a $3.95M loss on remeasurement of a related-party convertible note.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.